SynCardia continues to invest in its leadership team with Peter Spadaro’s appointment as President and CCO.
SynCardia Systems, LLC, manufacturer of the world’s only clinically-proven and commercially approved total artificial heart, is excited to announce the appointment of Peter Spadaro as the new President and Chief Commercial Officer. Peter will be responsible for oversight of the global Sales and Marketing Organizations and for driving the company’s sales growth. He will assume the new role on April 2, 2019 and will report to SynCardia’s recently appointed CEO, Don Webber.
“With the addition of Peter, we are now well positioned to expand our reach and presence throughout the global markets. Peter has spent his entire career building and nurturing clinician relationships and building strong customer centric marketing and sales programs. He brings a wealth of knowledge and experience to our leadership team and we are all thrilled to have him join us.”
Peter started his career at St. Jude Medical as a Sales Representative in New York City. During his almost 30-year career with St. Jude Medical he progressed through the organization’s Sales and Marketing organizations taking on leadership roles that included Vice President of Global Marketing, Vice President of Cardiovascular Sales, and Division Vice President of Cardiac Rhythm Management to name a few. Peter comes to SynCardia from his recent leadership role at Medtronic as Senior Director of Sales, Cardiac Surgery. He holds a Bachelor’s Degree from Fordham University.
“I am very excited to have the opportunity to work with Don and the talented and devoted team at SynCardia to deliver the vision of our company and the efficacy of our TAH technology to HF Surgeons and Cardiologists around the globe. The commercial team will be focused on creating the messaging, engagement and awareness necessary to position our therapy as a significant tool in treating patients with advanced Heart Failure. “
Together, Don and Peter bring over 60 years of medical device leadership and management experience to SynCardia.
Headquartered in Tucson, Ariz., SynCardia manufactures the world’s only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world.
By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn’t an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).